Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Leases (2022 - 2025)

Atara Biotherapeutics' Current Leases history spans 4 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Current Leases fell 0.96% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 0.96%, while the annual FY2025 figure was $1.0 million, 0.96% down from the prior year.
  • Current Leases reached $1.0 million in Q4 2025 per ATRA's latest filing, down from $2.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $13.1 million in Q1 2024 to a low of $832000.0 in Q1 2023.
  • Average Current Leases over 4 years is $3.0 million, with a median of $990500.0 recorded in 2024.
  • Peak YoY movement for Current Leases: soared 1472.96% in 2024, then dropped 1.84% in 2025.
  • A 4-year view of Current Leases shows it stood at $834000.0 in 2022, then rose by 9.71% to $915000.0 in 2023, then grew by 13.44% to $1.0 million in 2024, then fell by 0.96% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Current Leases are $1.0 million (Q4 2025), $2.2 million (Q2 2025), and $12.8 million (Q1 2025).